ArticleJournal of cachexia, sarcopenia and muscle2026
A Murinized Bimagrumab Analogue Increases Skeletal Muscle Mass and Improves Cardiometabolic Remodelling in Experimental Hypertrophic Cardiomyopathy.
Article in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundHypertrophic cardiomyopathy (HCM) involves left ventricular hypertrophy and metabolic dysfunction. Given the role of skeletal muscle in systemic metabolism, we investigated whether activin type II receptor inhibition with CDD866, a murinized bimagrumab analogue that induces skeletal muscle hypertrophy, improves physical performance and cardiometabolic remodelling in established HCM.
methodsTwenty-four-week-old male mice harbouring the cardiac myosin R403Q mutation received CDD866 or isotype antibody (20 mg/kg subcutaneously every 3 days) for 4 weeks; wild-type (WT) littermates received isotype antibody. Assessments included body composition, muscle imaging and histology, grip strength, treadmill exercise, glucose tolerance, echocardiography, cardiac histopathology, myocardial substrate oxidation by
resultsCompared with R403Q placebo, CDD866 increased lean mass (22.5 ± 0.6 vs. 18.7 ± 0.5 g; p < 0.001), grip strength (135.3 ± 3.4 vs. 99.9 ± 4.3 cN; p < 0.0001) and treadmill distance (99.8 ± 1.7 vs. 77.2 ± 3.2 m; p < 0.0001). Hindlimb muscle volume increased by 24 ± 8% (p < 0.05), and individual muscle weights increased by 44%-87% (all p < 0.0001). CDD866 reduced total left ventricular wall thickness (1.80 ± 0.03 vs. 1.98 ± 0.03 mm; p < 0.001) and improved E/A ratio (1.31 ± 0.04 vs. 0.99 ± 0.04; p < 0.001) and early diastolic mitral annular velocity (18.6 ± 0.7 vs. 14.0 ± 0.7 mm/s; p < 0.01). Cardiomyocyte cross-sectional area and myocardial fibrosis decreased by 32 ± 6% (p < 0.0001) and 69 ± 31% (p < 0.01), respectively. Glucose tolerance was impaired in R403Q mice versus WT (p < 0.01), with a nonsignificant reduction in AUC following CDD866 (p = 0.223). CDD866 increased the fractional contribution of fatty acids to myocardial oxidative metabolism (0.66 ± 0.02 vs. 0.38 ± 0.05; p < 0.01) and reduced
conclusionsCDD866 increased skeletal muscle mass and performance alongside improvements in cardiac remodelling, diastolic function and myocardial metabolism in established experimental HCM. Activin receptor inhibition offers a promising therapeutic avenue for HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.